{
    "nct_id": "NCT03953157",
    "official_title": "Improving Health of Women on Aromatase Inhibitors",
    "inclusion_criteria": "* At least 6 months since breast cancer diagnosis up to 2 years since diagnosis.\n* Diagnosed with localized breast cancer, up to stage IIIa.\n* Has been taking aromatase inhibitor (AIs) for at least six months.\n* Has been experiencing mild to moderate arthralgia (joint pain) for at least 2 months determined by the Brief Pain Inventory (BPI).\n* At least 6 months post chemotherapy or radiation treatment.\n* Subjects must be in good health as determined by medical history, physical examination, iDXA scan and clinical laboratory measurements.\n* Postmenopausal either natural or surgical or postmenopausal caused by ovarian suppression treatments administered to premenopausal women.\n* Currently taking aromatase inhibitor medication.\nHealthy volunteers allowed\nMust be FEMALE",
    "exclusion_criteria": "* Diagnosed with metastatic breast cancer.\n* Currently undergoing chemotherapy or radiation treatment.\n* Food allergies of any kind, or any medical condition requiring mandatory dietary restrictions.\n* A bone mineral density (BMD) T score less than -1, or fracture since taking AIs, or current use of glucocorticoids.\n* Taking bisphosphonates or any other medication for bone loss.\n* Significant cardiac, pulmonary, renal, liver or psychiatric disease.\n* Currently undergoing or engaging in a regular exercise program.\n* Muscular, orthopedic, or cardiovascular limitations that would prevent full participation in exercise.\n* Body mass index (BMI) greater than 40 kg/m^2.",
    "miscellaneous_criteria": ""
}